Dna heterogeneity determined by flow cytometry in prostatic adenocarcinoma—necessitating multiple site analysis
Authors:
- 1 December 1995
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 27 (6) , 329-335
Abstract
Although DNA ploidy analysis of prostate cancer is generally associated with grade, stage, clinical outcome, and responsiveness to androgen therapy, one possible reason cited for contrary reports may be tumor heterogeneity. A preliminary report using flow cytometric analysis of punch biopsies demonstrated DNA heterogeneity in five of nine patients. We evaluated 75 patients by cutting whole mounts of formalin fixed prostatectomy tissue every 0.6 cm. All malignant areas and a selected normal area were circumscribed, excised, remounted, and 1–3 50 μ thick sections removed. The nuclei were extracted by a Hedley technique and the DNA stained with propidium iodide. Each whole mount had an average of 1 distinct malignant area (range of 1–6 areas per whole mount block). Nuclei were analyzed on a Becton Dickinson (San Jose, CA) FACScan flow cytometer equipped with RFIT DNA software program. After excluding histograms with CVs > 8.0% and/or “suspicious” diploid histograms having a right “shoulder,” 75 or 87 patients still had ≥2 malignant sites available for analysis (average 4, range 2–9 malignant sites/patient). The 322 histograms had an average CV of 4.4%. Thirty of 75 patients (40%) showed DNA heterogeneity in multiple samples taken from the same prostate. There were 37 prostates with only diploid (D), 1 with only tetraploid (T), 7 with only aneuploid (A), 20 with D plus A, 7 with D plus T, 2 with D plus T plus A, and 1 with a D plus suspected hypodiploid DNA content. Exclusion of the tetraploid and “near diploid aneuploid” cases still resulted in 16% (12/75) of the patients having a diploid versus aneuploid DNA content heterogeneity. Because 40% of the prostates contained a different ploidy depending on which area was sampled, this report suggests multiple sites of malignancy must be analyzed to more accurately assess the ploidy status of prostatic adenocarcinoma.Keywords
This publication has 15 references indexed in Scilit:
- Consensus review of the clinical utility of dna content cytometry in prostate cancerCytometry, 1993
- Guidelines for implementation of clinical DNA cytometryCytometry, 1993
- Flow cytometric determination of breast tumor heterogeneityCancer, 1991
- Regional heterogeneity in breast carcinoma: Thymidine labelling index, steroid hormone receptors, dna ploidyInternational Journal of Cancer, 1991
- Variability in dna measurements in multiple tumor samples of human colonic carcinomaCancer, 1991
- Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancerCytometry, 1991
- Flow cytometric DNA content analysis in primary lung cancer: Comparison of results from fresh and paraffin‐embedded specimensJournal of Surgical Oncology, 1990
- Intratumoral variations in dna distribution patterns in mammary adenocarcinomasCytometry, 1989
- Stage D1 Prostatic Adenocarcinoma: Significance of Nuclear DNA Ploidy Patterns Studied by Flow CytometryMayo Clinic Proceedings, 1988
- Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.Journal of Histochemistry & Cytochemistry, 1983